Oncology Research Services
Conduct safer, smarter, faster oncology research with solutions and services that enable collaboration and visibility, ensure compliance, and streamline operations for your cancer clinical trials.
Advarra’s Contributions to Oncology Research
of industry-initiated oncology trials in the US rely on Advarra solutions
of NCI designated cancer centers conducting clinical trials are supported by Advarra’s IRB
investigators rely on Advarra for research participants protections and research performance optimization
By the Numbers
of NCI designated cancer centers collaborate through the Onsemble community
of NCI designated cancer centers manage their trials with OnCore CTMS
research sites conduct gene therapy research with Advarra’s IBC
business day average IBC review timeline for NCI designated cancer centers
protocol calendars developed for oncology trials
oncology coverage analyses performed for oncology trials in 2021
increase in startup funding with budget negotiation service
of delivering optimal outcomes through all phases in research and development for global oncology start-ups
mid-sized biopharma and biotech firms leveraged strategic regulatory guidance, clinical development planning, and GxP quality solutions
20% More Enrollment, 50% Less Screen Failure, 21% Fewer Protocol Deviations
Learn how a top-20 pharmaceutical company leveraged the Longboat platform to facilitate optimal execution and increase engagement for a uniquely challenging global Phase III breast cancer study.
Sponsors and CROs
Ensure efficient, compliant study conduct for every oncology trial with Advarra’s expert review services, experienced global consultants, and integrated study management, site training, and participant engagement platform.
IRB Review
- Experienced in overseeing oncology research and led by experts in the field, Advarra’s IRB understands the latest developments to ensure appropriate protections regardless of unique design or complexity.
- With a roster reflecting the robust expertise oncology research institutions expect, sites are more likely to defer oversight to Advarra as the central IRB. Expertise includes pediatric cancers, rare disease, internal medicine, hematology, women’s cancer, early phase/Phase I oncology, lymphoma, GI/colon cancer, and more.
- The IRB offers preliminary review feedback for draft protocols to help speed formal review.
IBC Review
- Speed study startup with the largest network of gene therapy-ready sites in the world: over 500 sites registered and prepared to conduct research involving genetic engineering.
- Our biosafety experts are knowledgeable in all prevalent types of genetic engineering and gene transfer technology employed oncology research (e.g., CAR T, cancer vaccines, oncolytics, etc.), including numerous individuals who have worked at NCI-designated cancer centers.
- Coordinated IRB/IBC reviews simplify and accelerate the review process.
- Ensure sites are prepared to conduct gene therapy research with biosafety site inspections, NIH registration, and other support.
Technology
- Supported by an intuitive, study-specific interface to ensure compliant and streamlined decentralized activities, the Longboat Platform helps identify sites with realistic patient populations to support complex studies.
- Enhance protocol compliance by decreasing deviations and queries via study specific trainings for site staff on key aspects of the study and procedures.
- Manage and oversee site performance globally and within specific regions that may require intervention.
- Clear patient criteria checklists decrease screen failures.
- Increase enrollment and retention via engaging materials and visit guides for both sites and participants.
Consulting
- Advance approvals while mitigating risk for bringing your therapy to market.
- Achieve your drug and device development goals with guidance from seasoned experts worldwide
- Innovate your clinical trials design and development with hands-on expertise from clinical practitioners
- Ensure global compliance and consistency with in-person and virtual audit support
Sites, Institutions, and Research Networks
Manage reporting requirements, ensure robust research oversight, share best practices, and increase financial viability to focus on what matters with Advarra’s industry-leading technology solutions, expert review services, resource-extending professional services, and a supportive site community.
IRB Review
- Experienced in overseeing oncology research and led by experts in the field, Advarra’s IRB understands the latest developments to ensure appropriate protections regardless of unique design or complexity.
- With a roster reflecting the robust expertise oncology research institutions expect, sites can feel confident deferring IRB oversight to meet single (sIRB) requirements. Expertise includes pediatric cancers, rare disease, internal medicine, hematology, women’s cancer, early phase/Phase I oncology, lymphoma, GI/colon cancer, and more.
- The IRB offers preliminary review feedback for draft protocols to help speed formal review.
- Advarra is the central IRB (cIRB) for dozens of therapeutically specialized site networks, including multiple oncology groups.
IBC Review
- Demonstrate your site is prepared to conduct gene therapy research by joining the largest network of gene therapy-ready sites in the world.
- Our biosafety experts are knowledgeable in all prevalent types of genetic engineering and gene transfer technology employed oncology research (e.g., CAR T, cancer vaccines, oncolytics, etc.), including numerous individuals who have worked at NCI-designated cancer centers.
- Coordinated IRB/IBC reviews simplify and accelerate the review process.
- Biosafety site inspections, NIH registration, SOP development services, and other support ensure your site can safely conduct research involving genetic engineering.
Technology
- Built for oncology research and recognized as the field’s preeminent technology platform, Advarra Technology Solutions enable efficient management of complex trials.
- Facilitate strategic decisions with reports on catchment area requirements, current accrual status, as well as reports on performance of oncology departments.
- Ensure complex CCSG reporting requirements are met, and articulate return on research investment with easy-to-use systems.
- The Onsemble Community, an unprecedented gathering of oncology research leaders and teams, creates a space for collaborative discussion, problem solving, and standardization that improves oncology research on a national scale.
Professional Services
- Alleviate administrative burden, increase research productivity, and maximize your resources with Advarra’s professional services.
- Simplify processes and ensure accurate adherence to protocols through efficient CTMS calendar building.
- Save time and confirm compliance with Medicare coverage analysis services.
- Budget negotiation helps researchers derive adequate funding for trial completion.
Grant Application Support
When developing a grant budget, how do you ensure you’ve included everything your project will need?
Maximize your funding request and avoid resources surprises down the road with Advarra’s support. Download our grant application checklist for an outline of common (and sometimes forgotten) elements you may need to include in your budget.
Need a budget estimate for your grant?
Read our Related Resources
Phase I Oncology Clinical Trials
This blog discusses what makes Phase I oncology trials complex and what IRBs need to know as they review a Phase I trial.
Cheryl Byers and Dr. John H. Stewart Discuss Diversity, Equity and Inclusion in Cancer Research
Diversity, equity, and inclusion (DEI) in cancer research are critical to clinical research. In this episode, Advarra’s Cheryl Byers and Dr. John H. Stewart have a discussion on what is DEI, the current climate of DEI in cancer research, and considerations to improve DEI in clinical trial enrollment and retention.
Q&A – How Medicare’s New Imaging Program Affects Clinical Trials in Oncology
Jake Meyer answers the most popular questions from his latest webinar: How Medicare’s New Imaging Program Affects Clinical Trials in Oncology.
